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ABSTRACT 
(-)-Englerin A ((-)-EA) has a rapid and 
potent cytotoxic effect on several types of cancer 
cell that is mediated by plasma membrane ion 
channels containing Transient Receptor Potential 
Canonical 4 protein (TRPC4). Since these channels 
are Ca2+ permeable it was initially thought that the 
cytotoxicity arose as a consequence of Ca2+ 
overload. Here we show that this is not the case and 
that the effect of (-)-EA is mediated by a heteromer 
of TRPC4 and TRPC1 proteins. Both TRPC4 and 
TRPC1 were required for (-)-EA cytotoxicity, 
however, although TRPC4 was necessary for the     
(-)-EA-evoked Ca2+-elevation, TRPC1 was not. 
TRPC1 either had no role or was a negative 
regulator of Ca2+ entry. By contrast, both TRPC4 
and TRPC1 were necessary for monovalent cation 
entry evoked by (-)-EA and (-)-EA-evoked cell 
death was dependent upon entry of the monovalent 
cation Na+. We therefore hypothesized that Na+/K+-
ATPase might act protectively by counteracting the 
Na+ load resulting from sustained Na+ entry. Indeed, 
inhibition of Na+/K+-ATPase by ouabain potently 
and strongly increased (-)-EA-evoked cytotoxicity. 
The data suggest that (-)-EA achieves cancer cell 
cytotoxicity by inducing sustained Na+ entry 
through heteromeric TRPC1/TRPC4 channels and 
that the cytotoxic effect of (-)-EA can be potentiated 
by Na+/K+-ATPase inhibition. 
 
 (-)-Englerin A ((-)-EA) is a sesquiterpene 
from the bark of the African plant Phyllanthus 
engleri. Its isolation was first reported in 2009 
alongside a NCI60 human tumour cell line screen 
demonstrating its rapid cytotoxic potential, with 
potency in particular against renal cell carcinoma 
cell lines (1). Currently approved treatments for 
renal cell carcinoma are of limited efficacy and are 
often toxic. Therefore, there has been keen interest 
in the discovery of (-)-EA and methods for its 
synthesis (2-5). A larger screen revealed that (-)-EA 
kills cells from a wide range of lineages but again 
supported the absence of adverse effects on normal, 
non-cancerous, cells (6). Efforts to identify the 
cellular target of (-)-EA have suggested that it 
activates PKC theta and the Ca2+-permeable non-
selective channels formed by assembly of transient 
receptor potential canonical (TRPC) proteins 
TRPC4 and TRPC5 (6-8). PKC theta was involved 
in (-)-EA-induced cell death in the 786-0 renal 
carcinoma cell line (8) but was barely detectable in 
other (-)-EA sensitive cells (A498 renal carcinoma 
and A637 (ZLQJ¶VVDUFRPDGHULYHG cell lines) (6,7) 
and its proposed mechanism of action, promoting 
dependence on glucose while simultaneously 
starving cells of glucose (8), involves relatively 
slow gene regulatory events. Activation of an ion 
channel would be more consistent with the rapid     
(< 1 hour) onset of cell death induced by (-)-EA (7) 
and analysis of >500 well characterized cancer cell 
lines revealed that TRPC4 mRNA abundance is the 
feature best correlated with sensitivity to (-)-EA (6). 
In support, knockdown of TRPC4 in A498 and 
A673 cells offered protection against (-)-EA-
Na+ influx dependent (-)-Englerin A cytotoxicity 
2 
 
induced cell death (6). The related TRPC5 protein 
is, in contrast, rarely overexpressed in tumour cell 
lines (6). Notably, the latter study identified a few 
exceptions, cells with enhanced TRPC4 but low 
sensitivity to (-)-EA, indicating that upregulation of 
TRPC4 is not the sole factor imparting (-)-EA 
sensitivity. Although ion channels are increasingly 
suggested to have important roles in cancer 
development and progression, inhibitors, rather 
than activators, represent the more obvious 
approach for drug discovery. Therefore, it is 
important to better understand how activation of 
TRPC4-containing channels by (-)-EA results in 
rapid cancer cell death. 
 
RESULTS 
To investigate mechanisms of (-)-EA-
induced cytotoxicity we studied two (-)-EA-
sensitive cancer cell lines: A498 renal cell 
carcinoma cells and Hs578T triple-negative breast 
carcinoma cells (Fig. 1A and B). In both cell types, 
knockdown of TRPC4 suppressed (-)-EA-evoked 
cytotoxicity (Fig. 1C and D). 
Current-voltage relationships of (-)-EA-
evoked responses in A498 and Hs578T cells lacked 
the seat-like inflection of TRPC4 homomers, 
suggesting that the TRPC4 proteins are in 
heteromers with TRPC1 (Fig. 2A and B) (7). To test 
the principle of whether (-)-EA can activate 
TRPC1/TRPC4 heteromers, a stable HEK 293 cell 
line inducibly expressing a TRPC4-TRPC1 
concatemer was established (Fig. 3A and B). 
Analysis of the current-voltage relationship, which 
lacked the seat-like inflection of TRPC4 homomers 
and closely resembled that of A498 and Hs578T 
cells (Fig. 2B) (7), confirmed that the concatemer 
formed a functional heteromeric channel (Fig. 3C 
and D). Measurement of changes in intracellular 
Ca2+ concentration revealed that although (-)-EA 
was 2.5-fold less potent at this TRPC4-TRPC1 
channel, compared with the TRPC4 homomer, 
importantly it was able to activate the heteromer at 
nanomolar concentrations (Fig. 3E and F). The 
involvement of TRPC1 in (-)-EA-induced 
cytotoxicity was therefore assessed by knockdown 
of endogenous TRPC1 in the cancer cell lines. 
Similar to TRPC4 knockdown, TRPC1 knockdown 
protected against (-)-EA-induced cytotoxicity (Fig. 
4A and B). The data suggest that (-)-EA evokes 
cytotoxicity via heteromeric TRPC1/TRPC4 
channels and that both TRPC1 and TRPC4 are 
important. 
(-)-EA triggers elevation of intracellular 
Ca2+ (Fig. 5A and B), leading to the hypothesis that 
Ca2+ overload mediates the cytotoxicity (7). 
Consistent with this hypothesis, TRPC4 
knockdown dramatically suppressed the elevation 
in intracellular Ca2+ (Fig. 5C-E). In stark contrast, 
TRPC1 knockdown slightly (A498) or strongly 
(Hs578T) increased the Ca2+ response (Fig. 5F-H). 
The data suggest that TRPC4 and TRPC1 make 
opposite contributions to (-)-EA-evoked Ca2+ entry, 
with TRPC4 being positive and TRPC1 being null 
or negative. Yet they are both subunits in the same 
channel and both required for (-)-EA-evoked 
cytotoxicity. 
Since Ca2+ entry was not correlated with 
cytotoxicity we considered an alternative signal 
mediated by TRPC1/TRPC4 heteromeric channels 
± monovalent cation entry, which under 
physiological conditions is Na+ entry. To 
investigate monovalent cation entry in the absence 
of complicating efflux signals we measured 
unidirectional influx of the surrogate cation 
thallium (Tl+), which can be detected by adding Tl+ 
to the extracellular solution and measuring the 
resulting elevation of intracellular Tl+ with the Tl+ 
indicator FluxORTM. This technique reliably 
detected exogenously expressed TRPC4 homomer 
and TRPC4-TRPC1 concatemer channel activity 
(Fig. 6A) in HEK 293 cells and (-)-EA responses in 
A498 and Hs578T cells but not in (-)-EA insensitive 
UMRC2 cells (Fig. 6B and C). As expected, the 
A498 and Hs578T responses were suppressed by 
TRPC4 knockdown (Fig. 6D-F). Moreover, they 
were suppressed by TRPC1 knockdown (Fig. 6G-
I). To further test the role of TRPC1 in monovalent 
permeability we performed whole-cell patch-clamp 
recordings where the majority of the ionic current is 
dependent on flux of monovalent cations. These 
experiments were challenging because the current 
responses were commonly not clearly resolved, but 
again the responses were suppressed by TRPC1 
knockdown (Fig. 7). The data suggest that 
monovalent permeability through TRPC1/TRPC4 
heteromers correlates with the cytotoxicity of           
(-)-EA. 
 The idea that monovalent cation and not 
Ca2+ permeability mediates (-)-EA-evoked 
cytotoxicity was at odds with our previous 
observation that decreased extracellular Ca2+ 
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concentration afforded protection against (-)-EA-
induced cytotoxicity (7). We therefore considered 
an alternative explanation for this protection in 
which channel activity (and thus total monovalent 
cation flux) is Ca2+-dependent (9). In support of this 
explanation, lowering extracellular Ca2+ decreased 
the influx of not only Ca2+ but also Tl+ through 
TRPC4-TRPC1 concatemers expressed in HEK 293 
cells (Fig. 8) and the endogenous (-)-EA-activated 
channels in A498 and Hs578T cells (Fig. 9). The 
data suggest that the Ca2+-dependence of channel 
activity explains the Ca2+-dependence of (-)-EA 
cytotoxicity. 
 To investigate if Na+ is the trigger for           
(-)-EA-induced cytotoxicity, Na+ was substituted 
progressively by the larger non-permeant cation            
N-methyl-D-glucamine (NMDG+). Strikingly this 
resulted in progressive protection against 
cytotoxicity (Fig. 10A), evident at concentrations at 
which the switch to NMDG+ had no effect in the 
absence of (-)-EA (Fig. 10B). Protection did not 
result from a decrease in the potency of (-)-EA 
because partial substitution of Na+ by NMDG+ 
improved the EC50 for (-)-EA-induced cytotoxicity 
from 63.5 to 29.6 nM (Fig. 10C). Similar protective 
effects against (-)-EA cytotoxicity were observed 
for Hs578T cells (Fig. 10D). The data suggest that 
Na+ mediates (-)-EA-evoked cytotoxicity. 
 A feature of the (-)-EA effect on cell 
viability was that only about half of all cells died 
during the 6 hours exposure to (-)-EA (Fig. 1A and 
B). Although this is a relatively short time, we 
considered whether the cells contained a 
mechanism for protecting themselves against 
excess sustained Na+ entry and its cytotoxicity. 
Speculating that Na+/K+-ATPase might provide 
protection by counteracting Na+ influx by ATP-
dependent Na+ extrusion, we inhibited Na+/K+-
ATPase with ouabain and tested a concentration of        
(-)-EA close to the EC50 for A498 cytotoxicity (Fig. 
1A). Ouabain conferred a marked increase in 
cytotoxicity such that at 30 nM almost 85% of the 
cells now died within the 6 hours (Fig. 10E). 
Ouabain alone was without effect DWQ0 (Fig. 
10F). Ouabain not only increased the number of 
dead cells but also the potency of (-)-EA; 10 nM 
ouabain shifting the EC50 from 45.2 to 23.5 nM 
(Fig. 10G). A similar but smaller effect of ouabain 
was observed on (-)-EA-induced Hs578T cell death 
(Fig. 10H). The data suggest that Na+/K+-ATPase 
protects against (-)-EA-evoked cytotoxicity. 
DISCUSSION 
In this study we show the surprising finding 
that (-)-EA cytotoxicity results from Na+ not Ca2+ 
influx through TRPC4-containing channels. This 
led us to reveal that Na+/K+-ATPase protects against 
the cytotoxicity and that ouabain, a Na+/K+-ATPase 
inhibitor, can enhance it. Reduced Na+/K+-ATPase 
activity has been observed in human renal cell 
FDUFLQRPDV DVVRFLDWHG ZLWK UHGXFHG ȕ1-subunit 
(10,11). Therefore, if (-)-EA is pursued as a 
therapeutic direction, it might be worthwhile to 
monitor Na+/K+-ATPase as an indicator of potential 
(-)-EA sensitivity. Additionally co-administration 
of a Na+/K+-ATPase inhibitor, such as digoxin, 
could be an approach to provoke or increase (-)-EA 
sensitivity and perhaps augment its anti-cancer 
effects. 
A key feature of (-)-EA cytotoxicity is its 
rapidity (7). Therefore, fast signalling mechanisms 
are presumably pivotal and slower mechanisms 
such as transcription, translation and protein 
degradation less relevant. Accordingly, we focused 
on effects of (-)-EA within 6 hours. Based on prior 
work and data shown here we suggest the following 
sequence of events: (-)-EA binds to TRPC1/TRPC4 
ion channels in the plasma membrane, which 
increases the probability of channel opening and 
leads to sustained increases in Ca2+ and Na+ influx 
through the channel pore. TRPC1 suppresses Ca2+ 
permeability (12), therefore, the global cytosolic 
Ca2+ elevation is relatively small and non-toxic. 
Nevertheless, Ca2+ concentration elevations near 
the channels facilitate their activity (Fig. 9). The 
Na+ influx elevates the global cytosolic Na+ 
concentration, stimulating Na+/K+-ATPase, a Na+-
dependent pump which utilises ATP to drive Na+ 
extrusion. In some cells, activity of the pump is 
insufficient to prevent Na+ accumulating to a 
cytotoxic threshold, so these cells die. In other cells, 
pump activity is sufficient and the cells successfully 
resist (-)-EA. Blockade of the pump negates 
protection afforded by the pump, so more cells die. 
We suggest therefore that (-)-EA-dependent 
cytotoxicity depends on (i) sufficient functional 
TRPC1/TRPC4 heteromeric channels at the plasma 
membrane and (ii) insufficient Na+/K+-ATPase 
activity to counteract the sustained cytosolic Na+ 
elevation caused by frequent TRPC1/TRPC4 
channel opening. 
 Previous work has focused on TRPC4 as 
the target for (-)-EA and our data support this 
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mechanism (Fig 1C). Although contribution of 
TRPC1 to the (-)-EA-evoked ionic current was 
previously suggested (7), the data shown here 
provide the first evidence that TRPC1 is also 
important for (-)-EA-evoked cytotoxicity. Analysis 
of CellMinerTM gene transcript data for NCI60 cell 
lines (13,14) reveals positive z scores indicative of 
elevated TRPC1 expression in all twelve (-)-EA-
sensitive cell lines studied by Ratnayake and 
colleagues (1) (Fig 11). Therefore, involvement of 
TRPC1 in (-)-EA cytotoxicity is unlikely to be 
restricted to the two cell lines tested in our study. It 
is unclear if a particular property of TRPC1 is 
important for (-)-EA cytotoxicity. TRPC1 slightly 
reduces (-)-EA potency, so does not contribute 
substantially by altering the binding or efficacy of 
(-)-EA (Fig 3F). It is possible that it contributes 
simply by increasing the total number of TRPC 
proteins available for channel formation. However, 
this would only be advantageous if the Na+ 
conductance and opening probability of 
heteromeric channels were equal to or greater than 
those of homomeric TRPC4 channels. This 
comparison has yet to be made for TRPC4 channels 
but TRPC1 markedly reduces the unitary 
conductance of the closely related TRPC5 channels 
(15-17). Also, although the influence of TRPC4 on 
the trafficking of TRPC1 is well documented 
(18,19) details of the reverse relationship, and so 
753&¶VLQIOXHQFHRQFHOOVXUIDFHFKDQQHOGHQVLW\
are lacking. 
 The mechanism by which Na+ mediates       
(-)-EA cytotoxicity is currently unknown. Our 
findings nevertheless suggest a hypothesis whereby 
excess sustained Na+ entry causes ATP depletion by 
forcing Na+/K+-ATPase into overdrive. Na+/K+-
ATPases are recognized as the major energy 
consumer in the brain (20) and this may also be true 
in cancer cells since Na+/K+-ATPases are the 
workhorses underlying Ca2+, H+, K+, Na+, Cl-, water 
and volume homeostasis. Inhibitors of Na+/K+-
ATPase would suppress this ATP utilisation but at 
the cost of failed ionic, osmotic and volume 
homeostasis. 
 In summary, this study has revealed a 
surprising biophysical phenomenon whereby Ca2+, 
the supreme signalling ion of eukaryotic biology, is 
not the mediator of (-)-EA-evoked cytotoxicity 
even though the target channels are Ca2+-permeable 
and the intracellular Ca2+ concentration does rise in 
response to (-)-EA. Instead it is the channel¶s Na+ 
permeability that mediates the cytotoxicity. How 
Na+ causes such an effect remains an open question, 
but what has become apparent is that Na+/K+-
ATPase protects cancer cells against the Na+ influx 
evoked by (-)-EA. Na+/K+-ATPase depletion, which 
occurs in cancer, could be a co-factor in (-)-EA 
sensitivity and pharmacological inhibition of the 
ATPase strikingly increased the vulnerability of 
cancer cells to (-)-EA. Recently Na+/K+ ATPase 
inhibitors, which have long been used in 
cardiovascular therapy, have been suggested to 
have anti-cancer effects (21). Although such 
inhibitors cause adverse effects they are commonly 
judged to be tolerable. Since (-)-EA also has 
adverse effects (6), efforts are needed to determine 
whether they would preclude translation towards a 
new anti-cancer therapy. 
 
EXPERIMENTAL PROCEDURES 
Materials - (-)-EA was purchased from 
PhytoLab and a 10 mM stock solution prepared in 
DMSO (stored at ±80 °C). To minimise (-)-EA 
aggregation 0.01% pluronic acid was included in 
experimental solutions as a dispersing agent. 
Ouabain octahydrate, dissolved in medium at         
0.5 mM, was purchased from Sigma-Aldrich. 
Intracellular calcium (Ca2+) (Fura-2) or 
thallium (Tl+) (FluxOR) measurements - For 
intracellular Ca2+ or Tl+ assays cells were plated at 
80-90% confluence in 96-well plates 24 hours prior 
to recordings (4 x 104 HEK T-REx cells; 1.8 x 104 
A498; 2.2 x 104 Hs578T; 1.2 x 104 UMRC2). To 
measure intracellular Ca2+ cells were incubated for 
1 hour at     37 °C in standard bath solution (SBS: 
135 mM NaCl,   5 mM KCl, 1.2 mM MgCl2, 1.5 
mM CaCl2, 8 mM glucose and 10 mM HEPES (pH 
WLWUDWHGWRXVLQJ1D2+FRQWDLQLQJȝ0IXUD-
2 acetoxymethyl ester (fura-2-AM, Molecular 
Probes) with 0.01 % pluronic acid. Cells were 
washed with SBS and incubated at room 
temperature for 20 minutes prior to recordings. To 
measure Tl+ influx cells were loaded with the 
FluxORTM dye for 1 hour at room temperature, 
transferred to assay buffer and stimulated with a Tl+ 
containing K+-free solution as per the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV0ROHFXODU3UREHV7R
assess the impact of extracellular Ca2+ on channel 
function using the FluxOR assay calcium free assay 
buffer (136.9 mM NaCl, 0.33 mM Na2HPO4,        
4.17 mM NaHCO3, 5.33 mM KCl, 0.44 mM 
KH2PO4, 0.49 mM MgCl2, 0.41 mM MgSO4,       
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5.55 mM D-glucose and 20 mM HEPES (pH 
titrated to 7.4 using NaOH)) and Ca2+-free stimulus 
buffer (140 mM Na gluconate, 2.5 mM K gluconate, 
1 mM Mg gluconate and 20 mM HEPES (pH 
titrated to 7.4 with NaOH)), to which a range of 
CaCl2 and Ca gluconate concentrations were 
supplemented respectively, were used. 
Measurements were made on a fluorescence plate 
reader (Flexstation, Molecular Devices). Fura-2 
was excited at 340 nm and 380 nm and emitted light 
collected at 510 nm, with measurements shown as 
WKH FKDQJH LQ IOXRUHVFHQFH ) UDWLR ¨)340/380). 
FluxOR was excited at 485 nm and emitted light 
collected at 520 nm, measurements expressed as a 
ratio increase over baseline (F/F0), with vehicle 
(DMSO) values subtracted from (-)-EA values at 
HDFKWLPHSRLQW¨))0).  
 Determination of cell viability - For cell 
viability assays cells were seeded onto 96-well 
plates 24 hours prior to WST-1 measurements          
(4 x 103 A498; 7.5 x 103 Hs578T; 5 x 103 UMRC2; 
1.5 x 104 HEK T-REx cells). The cell proliferation 
reagent WST-1 (Roche) was used as per the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV 5HGXFWLRQ RI WKH
tetrazolium salt WST-1 to formazan by 
mitochondrial dehydrogenases was determined by 
absorbance measurement at 450 nm. Cell death, so 
loss of mitochondrial dehydrogenase activity, was 
inferred from a decrease in this reaction. 
Background absorbance at the reference 
wavelength 655 nm was subtracted (Bio-Rad 
L0DUN 0LFURSODWH $EVRUEDQFH 5HDGHU .UHE¶V
buffer (125 mM NaCl, 3.8 mM KCl, 1.5 mM 
MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3,            
1.2 mM CaCl2, 8 mM glucose, pH 7.4), instead of 
medium, was used to facilitate substitution of NaCl 
for N-Methyl-D-Glucamine (NMDG).   
 Cell culture and expression systems - 
Human embryonic kidney T-RExTM-293 (HEK      
T-REx, Invitrogen) cell lines stably expressing 
KXPDQ 753&ȕ RU KXPDQ 753& XQGHU D
tetracycline inducible promoter have been 
described previously (7,22). A HEK T-REx cell line 
VWDEO\ H[SUHVVLQJ D KXPDQ 753&ȕ-TRPC1 
chimera was generated similarly and validated by 
ZHVWHUQ EORW DQG ELRSK\VLFDO DQDO\VLV  ȝJPO
tetracycline (Tet) was added to cells for 24 hours to 
induce channel expression. These HEK 293 cells 
ZHUH FXOWXUHG LQ 'XOEHFFR¶V PRGLILHG (DJOH¶V
medium GlutaMAX with 4.5 g/L D-glucose and 
pyruvate (Gibco) supplemented with the selection 
DQWLELRWLFV  ȝJP/ EODVWLFLGLQ DQG  ȝJP/
zeocin (InvivoGen). A498 cells were from ATCC 
and were cultured in Minimum Essential Medium 
(MEM) Eagle medium with EBSS, L-glutamine, 
2.2 g/L NaHCO3 (PAN-biotech, Germany) 
supplemented with sodium pyruvate. Hs875T cells, 
from ATCC, and UMRC2 cells, a generous gift 
from Prof Eamonn Maher, University of 
Cambridge, were cultured in RPMI 1640 medium 
with L-glutamine (Gibco). All media were 
supplemented with 10 % FBS, penicillin                   
(50 units/mL) and streptomycin (0.5 mg/mL) and 
grown at 37 °C in a 5 % CO2 incubator.  
 Cells were transfected at 90% confluence 
with 40 nM siRNA (Table 1) using Lipofectamine 
2000 (Invitrogen) in OptiMEM (Gibco) according 
WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV 0HGLXP ZDV
replaced after 5 hours and cells were used for 
experimentation 48-72 hours after transfection. 
siRNAs used: Silencer® Negative Control No. 1 
(#AM4611) and human TRPC1 (ID: 138932) from 
Ambion and ON-TARGETplus Non-targeting Pool 
(#D-001810-10-05) and human TRPC4 (#L-0065-
10-01) from Dharmacon.  
 Concatemer construct - Human TRPC4 and 
TRPC1 were cloned upstream and downstream 
respectively of a four amino linker (ASAS), flanked 
by AgeI and SacII restriction endonuclease sites, 
that had previously been introduced into 
SF'1$72 (22) 753&ȕ LQFOXGLQJ DQ           
N-terminal Kozak sequence, was inserted between 
BamHI and AgeI restriction sites using 
K753&ȕSF'1$72 (7) as a PCR template 
IRUZDUGSULPHU¶$*7&**$7&&*&&$&&$7 
**&7&$*77&7$77$&$$$$*¶ DQG UHYHUVH
SULPHU¶$*77$&&**7&$$7&77*7**7&$ 
&*7$$7&77&¶753&ZDVLQVHUWHGEHWZHHQ
SacII and XbaI restriction sites using 
hTRPC1/pIRES (23) as a PCR template (forward 
SULPHU ¶ $&7&&*&**&$7*$7**&**&&&   
7* ¶ DQG UHYHUVH SULPHU ¶ $*7&7&7$*$ 
TTAATTTCTTGGATAAAACATAGCATATTT
$*¶ 
 Electrophysiology - Borosilicate glass 
capillaries with an outside diameter of 1 mm and an 
inside diameter of 0.58 mm (Harvard Apparatus, 
USA) were used as the basis for patch pipettes. 
Pipettes were pulled using a PP-830 vertical 2-stage 
pipette-puller (Narishige, Tokyo, Japan). Pipette 
resistances after fire-polishing and filling with 
pipette solution were 2- 0ȍ 3LSHWWHV ZHUH
Na+ influx dependent (-)-Englerin A cytotoxicity 
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mounted on a CV-4 head-stage (Molecular Devices, 
USA) connected to a 3-way coarse manipulator and 
micromanipulator (Mitutoyo, Japan). The electrode 
was a Ag/AgCl wire. Electrical signals were 
amplified and recorded using an Axopatch 200B 
amplifier and pCLAMP 10 software (Molecular 
Devices). Data were filtered at 1 kHz and sampled 
digitally at 3 kHz via a Digidata 1440A analogue-
to-digital converter (Molecular Devices). Analysis 
was performed off-line using Clampfit 10.2 
(Molecular Devices) and Origin 8.6 software 
(OriginLab). Recordings were made at room 
temperature and with SBS as the extracellular 
solution. The standard patch pipette solution 
contained: 145 mM CsCl, 2 mM MgCl2, 10 mM 
HEPES, 1 mM EGTA (free acid), 5 mM ATP 
(sodium salt) and 0.1 mM Na.GTP (sodium salt), 
titrated to pH 7.2 with CsOH.  
 Quantitative real-time RT-PCR - Total 
RNA was extracted using TRI-reagent (Sigma-
Aldrich) followed by DNase I (Ambion) treatment. 
ȝJRIWRWDO51$ZDVXVHGIRUUHYHUVHWUDQVFULSWLRQ
(RT) using oligo-dT primers (Ambion) and AMV 
RT enzyme (Ambion). Real-time PCR was 
conducted using a Roche LightCycler. PCR primers 
XVHG DUH ȕDFWLQ IRUZDUG ¶ 7&*$*&$$*$*$ 
7**& ¶ DQG UHYHUVH ¶ 7*$$**7$*777 
&*7**$7*¶KXPDQ753&IRUZDUG¶77$* 
&*&$7*7**&$$¶DQGUHYHUVH¶&&$CTTA 
&7*$**&7$&7$$7 ¶ DQG KXPDQ 753&
IRUZDUG ¶ $77$*&77&$&****7 ¶ DQG
UHYHUVH¶*777$*$7&$7$*7&7$7$&7$*$ 
*7&&¶ 
 Western blotting for TRP proteins - Cells 
were harvested in lysis buffer (10 mM Tris, pH 7.4, 
150 mM NaCl, 0.5 mM EDTA, 0.5 % Nonidet P40 
substitute) containing protease inhibitor cocktail 
(Sigma). Equal protein amounts were loaded on 8% 
gels and resolved by electrophoresis. Samples were 
transferred to PVDF membranes and labelled 
overnight with anti-TRPC1 (1:1000, NeuroMab 
clone 1F1) or anti-ȕ-actin (200 ng/mL, Santa Cruz). 
Horse radish peroxidase donkey anti-mouse 
secondary antibody (Jackson ImmunoResearch) 
and SuperSignal Pico/Femto detection reagents 
(Pierce) were used for visualisation. 
 Statistical analysis - Averaged data are 
shown as mean ± standard deviation. Data were 
produced in pairs and analysed statistically with 
two-sample t tests or one-way ANOVA using 
OriginPro 8.6 software (OriginLab). 
Electrophysiological data (Fig. 7) were analysed 
with Mann Whitney U-test. Statistically significant 
difference is indicated by * (p<0.05), ** (p<0.01) or 
*** (p<0.001)³1´LVXVHGWRGHQRWHWKHQXPEHURI
independent data points, each point representing the 
mean value from a single independent experiment. 
5HSUHVHQWDWLYH WUDFHV FRQWDLQ ³Q´ UHSOLFDWHV IUom 
within a single experiment. 
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FIGURE 1. TRPC4 is important for (-)-EA-evoked cytotoxicity. (A,B) Reductions in A498 and Hs578T 
cell viabilities caused by 6 hour exposures to (-)-EA relative to vehicle control; determined by WST-1 assay. 
Mean and standard deviation values are plotted and the fitted curves are Hill Equations (N=3).                         
(C) Reductions in cell viabilities 72 hours after transfection with control siRNA or TRPC4 siRNA. Each 
data point represents a value from an independent experiment, with mean and standard deviation values 
indicated alongside (N=4). (* p<0.05; two-sample t-test) (D) Knockdown of TRPC4 mRNA. qRT-PCR 
determination of TRPC4 mRNA levels relative to ȕ DFWLQ P51$ $ DQG +V7 FHOOV KDG EHHQ
transfected 48 hours earlier with control siRNA or TRPC4-targeted siRNA (N=3). 
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FIGURE 2. (-)-EA-activated Hs578T channels are not TRPC4 homomers. (A) (-)-EA current in Hs578T. 
Whole-cell voltage-clamp recording of membrane current during ramp changes in membrane voltage from 
-100 to +100 mV applied every 10 seconds. Only currents sampled at -100 and +100 mV are displayed.    
100 nM (-)-EA was bath applied as indicated by the horizontal bar. (B) Full current traces during two ramp 
changes in voltage, one during the initial application of vehicle (DMSO) and the other after application of 
(-)-EA. Note the absence of a seat-like inflection characteristic of TRPC4 currents (24).  
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FIGURE 3. (-)-EA-activates heteromeric channels containing TRPC4 and TRPC1. (A) Schematic depicting 
the design of a TRPC4-TRPC1 concatamer (TRPC4/C1); N-terminal TRPC4ȕ (893 amino acids) linked to 
C-terminal TRPC1 (759 amino acids) via a flexible eight amino acid linker. (B) Western blot with anti-
TRPC1 antibody confirming tetracycline (Tet) inducible expression of the full length concatamer protein 
(predicted size = 191 kDa). Control HEK T-REx cells expressing monomeric TRPC1 protein are provided 
for comparison. (C) (-)-EA current in HEK T-REx cell expressing the TRPC4/C1 concatamer. Whole-cell 
voltage-clamp recording of membrane current during ramp changes in membrane voltage from -100 to +100 
mV applied every 10 seconds. Only currents sampled at -100 and +100 mV are displayed. 100 nM (-)-EA 
was bath applied as indicated by the horizontal bar. (D) Full current traces during two ramp changes in 
voltage, one during the initial application of vehicle (DMSO) and the other after application of (-)-EA.        
(E) Example of 96-well plate fura-PHDVXUHPHQWVRIWKHFKDQJH¨LQWKHLQWUDFHOOXODU&D2+ concentration 
evoked by (-)-EA in TRPC4 and TRPC4/C1 expressing HEK T-REx cells (n=4). (F) Mean data for 
experiments of the type shown in (E) measured between 1 and 2 minutes after application of a range of        
(-)-EA concentrations. Error bars indicate standard deviation and the fitted curves are Hill equations (N=3).  
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FIGURE 4. TRPC1 has a similar role to TRPC4 in (-)-EA-evoked cytotoxicity. (A) Reductions in A498 
and Hs578T cell viabilities caused by 6 hour exposures to 300 nM (-)-EA relative to vehicle control; 
determined by WST-1 assay. Cells had been transfected 72 hours earlier with control siRNA or TRPC1 
siRNA. Each data point represents a value from an independent experiment, with mean and standard 
deviation values indicated alongside (A498 (N=12), Hs578T (N=8)). (* p<0.05; two-sample t-test)                
(B) Knockdown of TRPC1 mRNA. qRT-PCR determination of TRPC1 mRNA levels relative WRȕDFWLQ
mRNA. A498 and Hs578T cells had been transfected 48 hours earlier with control siRNA or TRPC1-
targeted siRNA (N=3). 
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FIGURE 5. TRPC1 and TRPC4 make distinct contributions to (-)-EA-evoked Ca2+ elevation. (A,B) Mean 
data for fura-PHDVXUHPHQWVRIWKHFKDQJH¨LQWKHLQWUDFHOOXODU&D2+ concentration evoked by (-)-EA in 
A498 and Hs578T cells. Data are plotted as change in the ratio of fluorescence (F) emission for 340 and 
QPH[FLWDWLRQZDYHOHQJWKV¨)340/380). Error bars indicate standard deviation and the fitted curves are 
Hill equations (N=3). (C,D,F and G) Example of 96-well plate fura-2 measurements of the change in the 
intracellular Ca2+ concentration evoked by 300 nM (-)-EA (n=4). Experiments were paired comparisons of 
cells transfected with control scrambled siRNA or TRPC4 siRNA (C,D) / TRPC1 siRNA (F,G). (E,H) 
Summary for experiments of the type shown in (C,D,F and G) measured between 1 and 2 minutes after         
(-)-EA application. Each data point represents a value from an independent experiment, with mean and 
standard deviation values indicated alongside ((E) A498 (N=5), Hs578T (N=7); (H) A498 (N=9), Hs578T 
(N=6)). (* p<0.05; two-sample t-test)  
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FIGURE 6. TRPC1 and TRPC4 make similar contributions to (-)-EA-evoked Tl+ entry. (A) Measurement 
of thallium ion (Tl+) entry through TRPC channels using FluxOR. Example of 96-well plate FluxOR 
PHDVXUHPHQWVRIWKHFKDQJH¨LQWKHLQWUDFHOOXODU7O+ concentration upon application of extracellular Tl+ 
and 300 nM (-)-EA HEK T-REx cells expressing TRPC4 or TRPC4/C1 (n=3). The FluxOR measurements 
are displayed as the fluorescence intensity (F) relative to the initial fluorescence intensity (F0). (B) FluxOR 
measurements as for (A) for the cancer cell lines A498, Hs578T and UMRC2 (n=3). (C) Reductions in cell 
viabilities caused by 6 hour exposures to 300 nM (-)-EA relative to vehicle control; determined by WST-1 
assay. Each data point represents a value from an independent experiment, with mean and standard deviation 
values indicated alongside (N=3). Note the correlation between reduction in cell viability in (C) and the data 
in (B). (D,E,G and H) Example of 96-well plate FluxOR measurements upon application of extracellular 
Tl+ and 300 nM (-)-EA in A498 (D and G) and Hs578T (E and H) cells. (n=3). Experiments were paired 
comparisons of cells transfected with control scrambled siRNA or TRPC4 siRNA (D,E) / TRPC1 siRNA 
(G,H) (n=3). (F,I) Data for experiments of the type shown in (D,E,G and H) in which the rate of change of 
F was measured between 5 and 35 seconds after (-)-EA application. Each data point represents a value from 
an independent experiment, with mean and standard deviation values indicated alongside (A498 (N=4), 
Hs578T (N=3)). (* p<0.05 and ** p<0.01; two-sample t-test)  
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FIGURE 7. Suppression of (-)-EA-activated ionic currents by TRPC1 knockdown in A498 cells.                   
(A) Whole-cell voltage-clamp recording of membrane current during ramp changes in membrane voltage 
from -100 to +100 mV applied every 10 seconds. Only currents sampled at -100 and +100 mV are displayed. 
100 nM (-)-EA was bath applied as indicated by the horizontal bar. A498 cells had been transfected with 
control siRNA or TRPC1-targeted siRNA 72 hours earlier. (B) Current amplitudes at +100 mV with mean 
and standard deviation values indicated alongside (N=19 cells for each). (* p<0.05; Mann Whitney U-test)  
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FIGURE 8. (-)-EA-evoked Tl+ entry in TRPC4/C1 expressing HEK T-REx cells is Ca2+-dependent.             
(A) Example of 96-well plate fura-PHDVXUHPHQWVRIWKHFKDQJH¨LQWKHLQWUDFHOOXODU&D2+ concentration 
evoked by 300 nM (-)-EA in HEK T-REx cells induced to express the TRPC4-TRPC1 concatemer. 
Responses were observed in the presence of 0, 0.5, 1 and 1.5 mM extracellular Ca2+ ([Ca2+]ex) (n=4). (B) As 
for (A) but example of 96-ZHOO SODWH )OX[25 PHDVXUHPHQWV RI WKH FKDQJH ¨ in the intracellular Tl+ 
concentration upon application of extracellular Tl+ and 300 nM (-)-EA (n=4). (C) As for (A) but in the 
continuous presence of 1.5 mM extracellular Ca2+ plus 0, 1 or 2 mM EGTA to buffer Ca2+ (n=4). (D) As for 
(B) but in the continuous presence of 1.8 mM extracellular Ca2+ plus 0, 1 or 2 mM EGTA to buffer Ca2+ 
(n=4).   
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FIGURE 9. (-)-EA-evoked Tl+ entry in A498 and Hs578T cells is Ca2+-dependent. (A,B) Example of           
96-well plate FluxOR PHDVXUHPHQWVRIWKHFKDQJH¨LQWKHLQWUDFHOOXODU7O+ concentration upon application 
of extracellular Tl+ and 300 nM (-)-EA. Responses were observed in the presence of 0 or 1.5 mM 
extracellular Ca2+ ([Ca2+]ex) (n=4). (C,D) As for (A and B) but in the continuous presence of 1.8 mM 
extracellular Ca2+ plus 0 or 2 mM EGTA to buffer Ca2+ (n=4). (E,F) Summary data for experiments of the 
type shown in (A-D) in which the rate of change of F was measured between 5 and 35 seconds after (-)-EA 
application. Each data point represents a value from an independent experiment, with mean and standard 
deviation values indicated alongside ((E) (N=3), (F) (N=4)). Percentage values indicate decreases in the 
mean compared with the respective controls.  
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FIGURE 10. (-)-EA-evoked cytotoxicity is Na+-dependent and potentiated by ouabain. (A) Reduction of 
A498 cell viability after 6 hours treatment with 300 nM (-)-EA in 150 mM Na+ Krebs buffer and increasing 
replacement of Na+ by N-methyl-D-glucamine (NMDG+) to a maximum of 87.5 mM Na+ and 62.5 mM 
NMDG+. Each data point represents a value from an independent experiment, with mean and standard 
deviation values indicated alongside (N=3). (* p<0.05, ** p<0.01; One-way ANOVA with Bonferroni post 
hoc test) (B) As for (A) but in the absence of (-)-EA and shown as cell viability relative to 150 mM Na+ 
Krebs buffer (control) (N=3). (C) Concentration-dependent reduction in A498 cell viability in response to 
(-)-EA in Krebs buffer containing 150 mM Na+ (Na) or 100 mM Na+ and 50 mM NMDG+ (Na:NMDG) 
(N=5). The fitted curves are Hill equations with mid-points of 63.5 nM (Na) and 4.5 nM (Na:NMDG).      
(*** p<0.001; One-way ANOVA with post hoc Bonferroni test) (D) Reduction of Hs578T cell viability 
after 6 hours treatment with 300 nM (-)-EA in 150 mM Na+ (Na) or 100 mM Na+ and 50 mM NMDG+ 
(Na:NMDG) (N=3). (* p<0.05; two-sample t-test) (E) Reduction of A498 cell viability after 6 hours 
treatment with 30 nM (-)-EA plus 0, 1, 3, 10 and 30 nM ouabain 30 minutes prior to (-)-EA and during          
(-)-EA exposure (N=3). (*** p<0.001; One-way ANOVA with post hoc Bonferroni test) (F) As for (E) but 
in the absence of (-)-EA and shown as cell viability relative to 0 nM ouabain (control) (N=3). (G) Reduction 
of A498 cell viability after 6 hours treatment with (-)-EA in vehicle (control) and the presence of 10 nM 
ouabain (N=3). The fitted curves are Hill equations with mid-points of 45.2 nM (control) and 23.5 nM 
(ouabain). (*** p<0.001; One-way ANOVA with Bonferroni post hoc test) (H) Reduction of Hs578T cell 
viability after 6 hours treatment with 30 nM (-)-EA in vehicle (control) and the presence of 10 nM ouabain 
(N=7). (* p<0.05; two-sample t-test) 
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FIGURE 11. Comparison of TRPC4, TRPC1 and TRPC5 gene transcript levels in (-)-EA sensitive NCI60 
cell lines. TRPC4, TRPC1, TRPC5 gene transcript data from the CellMinerTM database (13,14) for NCI60 
cell lines identified by Ratnayake and colleagues to be killed by (-)-EA (1). The z scores reflect the number 
of standard deviations from the mean. BR, breast; CNS, central nervous system; LC, non-small cell lung; 
OV, ovarian; RE, renal. 
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